NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Rivaroxaban for the treatment of pulmonary embolism and the prevention of recurrent venous thromboembolism [ID569

Please sign and return to:

Marcia Miller, Technology Appraisal Administrator
Email: TACommA@nice.org.uk
Fax: +44 (0)20 7061 9819
Post: NICE, 10 Spring Gardens, London SW1A 2BU

I confirm that:

- I agree with the content of the statement submitted by British Society of Haemostasis and Thrombosis and consequently I will not be submitting a personal statement.

Name: Mark Crowther

Signed:

Date: 11th February 2013